nelarabine
Selected indexed studies
- Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia. (Blood Adv, 2024) [PMID:37389830]
- Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. (J Clin Oncol, 2020) [PMID:32813610]
- Nelarabine. (, 2012) [PMID:31643833]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia. (2024) pubmed
- Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. (2020) pubmed
- Nelarabine. (2012) pubmed
- Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). (2022) pubmed
- Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action. (2025) pubmed
- PMID:38320076 (2023) pubmed
- Nelarabine. (2008) pubmed
- Nelarabine-Induced Myelotoxicity. (2021) pubmed
- Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group. (2023) pubmed
- Nelarabine use in leukemias. (2006) pubmed